908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

908 Devices a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, announced that GlaxoSmithKline  has purchased an additional REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.

CES 2022 News: Moogsoft And Alesia Labs Team Up To Offer Greater Observability Features

“We are pleased that GSK has once again chosen our REBEL desktop device as part of its process development efforts to bring promising therapeutics to market,” said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. “The REBEL analyzer enables our biopharma customers to make critical decisions on optimizing cell cultures in minutes, and its small desktop footprint fits alongside bioreactors in process development labs.”

908 Devices notes there are now 15 customers owning multiple REBEL devices, more than double from one year ago. In addition, all 20 of the top 20 pharmaceutical companies are now using the company’s desktop devices, which include REBEL and ZipChip®, in their development process.

Recommended AI News: Xperi Launches Revolutionary Single Camera Solution For Driver And Occupancy Monitoring

[To share your insights with us, please write to sghosh@martechseries.com]